Clinical Trial Update: Immunoadsorption of LPS, C5a and IL-6 in Severe Sepsis and Septic Shock (ISASS-1) [Phase 2, Phase 3]

View source ↗

Summary

The ISASS-1 trial evaluating immunoadsorption to remove LPS, C5a, and IL-6 in severe sepsis and septic shock has completed Phase 2 and Phase 3 enrollment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sepsis
• Septic Shock

Drugs mentioned

• Immunoadsorption ISASS-1

Snippet

Sponsor: Charite University, Berlin, Germany | Conditions: Septicemia | Phase 2, Phase 3 | Status: COMPLETED